News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Analyst recommends buying Broadcom after its pullback, citing AI leadership and $32.8B free cash flow, with a $450 target and $360 stop.
  • Unified Patent Court granted InterDigital an injunction against Disney over HEVC patents covering 11 EU countries, increasing licensing risk for streaming services.
  • Webuy Global joined PATA and the China Inbound Tourism Alliance to build an AI-assisted inbound tourism ecosystem targeting China's reopening.
  • AI leadership and China's travel reopening are driving investor interest toward semiconductors and travel tech this hour.
  • European IP enforcement actions may raise near-term volatility for media and streaming stocks.

Latest Articles

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Opus Genetics, a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases, announced a virtual R&D Science Forum on June 16, 2026. The forum will feature expert speakers discussing the company's multi-asset gene therapy pipeline, including upcoming clinical trials targeting RDH12, MERTK, and RHO mutations, r…

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

Entrada Therapeutics announced that an independent Data Monitoring Committee has recommended advancing to Cohort 2 at an increased dose of 10 mg/kg in their ongoing Phase 1/2 ELEVATE-45-201 clinical trial for ENTR-601-45, a potential treatment for Duchenne muscular dystrophy (DMD) patients amenable to exon 45 skipping. Cohort 1 participants have mo…

BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026

BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026

BeyondSpring reported updated positive efficacy and safety results from its ongoing Phase 2 303 Study evaluating Plinabulin combined with pembrolizumab and docetaxel in metastatic non-small cell lung cancer patients who progressed after first-line immune checkpoint inhibitor therapy. The combination demonstrated favorable progression-free survival,…

Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy

Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy

Vera Therapeutics announced alignment with the U.S. FDA on an earlier eGFR analysis for the ORIGIN Phase 3 trial of atacicept, a therapy targeting BAFF and APRIL for adults with IgA nephropathy (IgAN). The revised analysis is now planned for Q3 2026, ahead of the previous 2027 timeline. Pending positive results, the company plans to submit a supple…

Victoria’s Secret & Co. Reports First Quarter 2026 Results

Victoria’s Secret & Co. Reports First Quarter 2026 Results

Victoria's Secret & Co. delivered a robust first quarter 2026 performance, with net sales rising 15% to $1.56 billion, surpassing guidance. Operating income increased significantly to $76 million from $20 million a year prior, supported by strong sales growth across key brands and improved gross margins. The company raised its full-year 2026 net sa…

Telix and United Imaging Announce Strategic Theranostics Collaboration

Telix and United Imaging Announce Strategic Theranostics Collaboration

Telix Pharmaceuticals Limited (TLX) and United Imaging Healthcare North America have signed a Memorandum of Understanding to collaborate on the integration of Telix's molecular imaging products with United Imaging's advanced scanner platforms and AI capabilities. The initial focus will be on the US evaluation of TLX101-Px, a PET imaging candidate u…

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

iBio has initiated dosing in its Phase 1 clinical trial for IBIO-600, a long-acting monoclonal antibody aimed at preserving muscle and improving body composition in adults with obesity. This milestone marks the company's transition to a clinical-stage biotech firm, showcasing progress in its AI-driven discovery platform and potential combination wi…

SOLV Energy Scales Up, Now Supporting Multiple 600+ MW Solar and Battery Projects Totaling More than 4 GW Across the U.S.

SOLV Energy Scales Up, Now Supporting Multiple 600+ MW Solar and Battery Projects Totaling More than 4 GW Across the U.S.

SOLV Energy has announced its involvement in multiple large-scale solar and battery energy projects across the U.S., totaling more than 4 gigawatts in capacity. This marks a significant scale-up in projects exceeding 600 MWdc, with a diverse geographic footprint and integrated energy infrastructure offerings, underscoring the company's leadership a…

X-energy Submits Xe-100 HTGR for UK Generic Design Assessment

X-energy Submits Xe-100 HTGR for UK Generic Design Assessment

X-energy has submitted its Xe-100 high temperature gas-cooled reactor (HTGR) design to the UK's Generic Design Assessment process, a key regulatory step towards licensing advanced nuclear technology in the UK. This submission supports plans to deploy up to 6 GW of nuclear capacity in partnership with Centrica, aiming to enhance UK energy security w…

Lumexa Imaging Announces Joint Venture with Hospital for Special Surgery (HSS) to Expand Advanced Outpatient Imaging in New York

Lumexa Imaging Announces Joint Venture with Hospital for Special Surgery (HSS) to Expand Advanced Outpatient Imaging in New York

Lumexa Imaging (NASDAQ: LMRI), a leading outpatient imaging provider, announced a strategic joint venture with Hospital for Special Surgery (HSS), a world leader in musculoskeletal health. This marks Lumexa's ninth joint venture and aims to broaden access to advanced outpatient imaging services in the New York metro area. The partnership leverages …

Kodiak AI Named to Inc.’s 2026 Best Workplaces List

Kodiak AI Named to Inc.’s 2026 Best Workplaces List

Kodiak AI, a Nasdaq-listed company specializing in AI-powered autonomous vehicle technology, has been named to Inc.'s 2026 Best Workplaces list, highlighting its exceptional company culture and commitment to employee development. The accolade underscores Kodiak's position as a leader in autonomous trucking technology, advancing safer and more effic…

Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Rezolute, Inc. announced positive interim data from its Phase 3 open-label upLIFT study evaluating ersodetug in patients with tumor hyperinsulinism (HI). With 8 participants enrolled (halfway to full enrollment), 6 have met the primary endpoint of at least 50% reduction in intravenous glucose requirements, and all were able to discontinue IV glucos…

Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism

Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism

Can-Fite BioPharma reports encouraging clinical observations from its Phase 2a pancreatic cancer study with its lead drug candidate Namodenoson, which exhibits a unique multi-pathway RAS signaling inhibition mechanism. The company underscores the importance of targeting KRAS-driven pancreatic ductal adenocarcinoma and notes prolonged disease contro…

Picard Medical / SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies

Picard Medical / SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies

Picard Medical, Inc., through its subsidiary SynCardia Systems, announced successful acute in vivo implant studies of its next-generation Emperor Total Artificial Heart (TAH). The studies demonstrated stable hemodynamic support and physiologic autoregulatory behavior in a large animal model, validating the independent dual motor ventricular design.…

Buy the Dip in Credo: Connectivity Demand Backs a Risk-Weighted Long

Buy the Dip in Credo: Connectivity Demand Backs a Risk-Weighted Long

Credo (CRDO) sold off after recent earnings, creating a tactical buying opportunity. The company sits at the center of AI infrastructure: high-speed SerDes, integrated circuits and active electrical cables. Despite stretched multiples - P/E ~122x and EV/sales ~38x - 202% YoY top-line growth reported in coverage and $283.7M of free cash flow give th…

Equity Supply Shock? AI Frenzy and Big Equity Raises Cloud Market Appetite

Equity Supply Shock? AI Frenzy and Big Equity Raises Cloud Market Appetite

Global markets showed surface calm even as an unfolding AI story and persistent uncertainty over U.S.-Iran talks created mixed signals. Anthropic confidentially filed for an IPO and SpaceX readies a major offering, while Alphabet disclosed plans to raise about $80 billion of equity, including a $10 billion private placement with Berkshire Hathaway.…

Bowman Secures Significant Mining-Related Awards

Bowman Secures Significant Mining-Related Awards

Bowman Consulting Group Ltd., a Nasdaq-listed national engineering services firm, announced it secured over $4 million in mining-related contracts. The awards cover engineering and geospatial services for critical minerals and precious metals projects across the U.S. and Mexico, reinforcing Bowman's growth in infrastructure-intensive natural resour…

U.N. Warns of Elevated Heat and Extreme Weather Risk as El Nino Develops

U.N. Warns of Elevated Heat and Extreme Weather Risk as El Nino Develops

The World Meteorological Organization has issued a forecast that a moderate, and possibly strong, El Nino is forming. Warm subsurface waters in the tropical Pacific are driving surface warming, raising the prospect of heightened global temperatures, more frequent heat extremes and shifts in regional rainfall patterns that could strain food supplies…